Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

43. Clinical benefit table: Orthovisc. Continuous outcome measures (1).

Study Time Treatment Outcome (scale) N of Pts Baseline Mean End of Study Mean Absolute Benefit Relative Difference
Bayramoglu 2003 End of treatment E: Orthovisc + PT Lequesene Index (0‐24) 16 12.4 9.1 ‐1.00 (I) ‐8.6% (I)
    C: PT   15 11.6 9.3    
Bayramoglu 2003 End of treatment E: Orthovisc + PT Lequesne Index (0‐24) 16 12.4 9.1 0.9 (W) 7.0% (W)
    C: Hylan G‐F 20 + PT   15 12.8 8.6    
Bayramoglu 2003 5‐13 wk E: Orthovisc + PT Lequesene Index (0‐24) 16 12.4 7.6 ‐2.6 (I) ‐22.4% (I)
    C: PT   15 11.6 9.4    
Bayramoglu 2003 5‐13 wk E: Orthovisc + PT Lequesne Index (0‐24) 16 12.4 7.6 ‐0.6 (I) ‐4.7% (I)
    C: Hylan G‐F 20 + PT   15 12.8 8.6    
Tascioglu 2003 1‐4 wk E: Orthovisc Pain on weight bearing (0‐100 mm VAS) 28 54.26 31.83 3.87 (W) 7.3% (W)
    C: 6‐MPA   27 53.10 26.80    
Tascioglu 2003 1‐4 wk E: Orthovisc Pain at rest (0‐100 mm VAS) 28 30.43 11.83 3.00 (W) 10.0% (W)
    C: 6‐MPA   27 29.90 8.30    
Tascioglu 2003 1‐4 wk E: Orthovisc Pain on walking (0‐100 mm VAS) 28 67.60 37.60 1.00 (W) 1.5% (W)
    C: 6‐MPA   27 69.00 38.00    
Tascioglu 2003 1‐4 wk E: Orthovisc Lequesne Index (0‐24) 28 10.23 7.86 ‐0.47 (I) ‐4.8% (I)
    C: 6‐MPA   27 9.86 7.96    
Tascioglu 2003 1‐4 wk E: Orthovisc Flexion (degrees) 28 108.70 116.36 1.52 (I) 1.4% (I)
    C: 6‐MPA   27 108.06 114.20    
Tascioglu 2003 5‐13 wk E: Orthovisc Pain on weight bearing (0‐100 mm VAS) 28 54.26 22.86 ‐16.80 (I) ‐31.6% (I)
    C: 6‐MPA   27 53.10 38.50    
Tascioglu 2003 5‐13 wk E: Orthovisc Pain at rest (0‐100 mm VAS) 28 30.43 12.00 ‐8.23 (I) ‐27.5% (I)
    C: 6‐MPA   27 29.90 19.70    
Tascioglu 2003 5‐13 wk E: Orthovisc Pain on walking (0‐100 mm VAS) 28 67.60 32.03 ‐17.03 (I) ‐24.7% (I)
    C: 6‐MPA   27 69.00 50.46    
Tascioglu 2003 5‐13 wk E: Orthovisc Lequesne Index (0‐24) 28 10.23 7.66 ‐1.77 (I) ‐17.9% (I)
    C: 6‐MPA   27 9.86 9.06    
Tascioglu 2003 5‐13 wk E: Orthovisc Flexion (degrees) 28 108.70 115.76 1.72 (I) 1.6% (I)
    C: 6‐MPA   27 108.06 113.40    
Tascioglu 2003 14‐26 wk E: Orthovisc Pain on weight bearing (0‐100 mm VAS) 28 54.26 40.96 ‐16.56 (I) ‐31.2% (I)
    C: 6‐MPA   27 53.10 56.36    
Tascioglu 2003 14‐26 wk E: Orthovisc Pain at rest (0‐100 mm VAS) 28 30.43 23.56 ‐3.43 (I) ‐11.5% (I)
    C: 6‐MPA   27 29.90 26.46    
Tascioglu 2003 14‐26 wk E: Orthovisc Pain on walking (0‐100 mm VAS) 28 67.60 51.16 ‐13.50 (I) ‐19.6% (I)
    C: 6‐MPA   27 69.00 66.06    
Tascioglu 2003 14‐26 wk E: Orthovisc Lequesne Index (0‐24) 28 10.23 8.46 ‐1.51 (I) ‐15.3% (I)
    C: 6‐MPA   27 9.86 9.60    
Tascioglu 2003 14‐26 wk E: Orthovisc Flexion (degrees) 28 108.70 114.60 4.36 (I) 4.0% (I)
    C: 6‐MPA   27 108.06 109.60    
Hizmetli 1999 1‐4 wk E: Orthovisc WOMAC pain (5‐25 Likert) 20 17.75 10.20 ‐7.80 (I) ‐44.6% (I)
    C: Saline   20 17.45 17.70    
Hizmetli 1999 5‐13 wk E: Orthovisc WOMAC pain (5‐25 Likert) 20 17.75 11.75 ‐6.25 (I) ‐35.4% (I)
    C: Saline   20 17.45 17.70    
Hizmetli 1999 14‐26 wk E: Orthovisc WOMAC pain (5‐25 Likert) 20 17.75 12.80 ‐5.90 (I) ‐33.7% (I)
    C: Saline   20 17.45 18.40    
Hizmetli 1999 45‐52 wk E: Orthovisc WOMAC pain (5‐25 Likert) 20 17.75 13.80 ‐5.60 (I) ‐32% (I)
    C: Saline   20 17.45 19.10    
Hizmetli 1999 1‐4 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 53.15 39.85 ‐13.40 (I) ‐25.8% (I)
    C: Saline   20 52.00 52.10    
Hizmetli 1999 5‐13 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 53.15 41.35 ‐11.30 (I) ‐21.7 (I)
    C: Saline   20 52.00 51.50    
Hizmetli 1999 14‐26 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 53.15 43.20 ‐10.45 (I) ‐20.2 (I)
    C: Saline   20 52.00 52.50    
Hizmetli 1999 46‐52 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 53.15 45.80 ‐8.25 (I) ‐16.0 (I)
    C: Saline   20 52.00 52.90    
Tekeoglu 1998 1‐4 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 45.50 34.30 3.10 (W) 6.8% (W)
    C: Betamethasone   20 45.60 31.30    
Tekeoglu 1998 5‐13 wk E: Orthovisc WOMAC function (17‐85 Likert) 20 45.50 30.90 ‐8.90 (I) ‐19.5% (I)
    C: Betamethasone   20 45.60 39.90    
Tekeoglu 1998 1‐4 wk E: Orthovisc Maximum flexion (degrees) 20 110.50 117.30 0.60 (I) 0.5% (I)
    C: Betamethsone   20 116.00 122.20    
Tekeoglu 1998 5‐13 wk E: Orthovisc Maximum flexion (degrees) 20 110.50 121.20 ‐1.55 (W) ‐1.3% (W)
    C: Betamethasone   20 116.00 128.25    
Kalay 1997 1‐4 wk E: Orthovisc + PT Activity pain (0‐100 mm VAS) 20 46.8 12.50 ‐11.4 (I) ‐30.7% (I)
    C: PT   20 37.1 14.20    
Kalay 1997 1‐4 wk E: Orthovisc + PT Spontaneous pain (0‐100 mm VAS) 20 26.1 5.80 ‐3.6 (W) ‐16.3% (W)
    C: PT   20 22.1 5.40    
Kalay 1997 1‐4 wk E: Orthovisc + PT Night pain (0‐100 mm VAS) 20 24.3 5.40 ‐2.8 (I) ‐12.9% (I)
    C: PT   20 21.7 5.60    
Kalay 1997 1‐4 wk E: Orthovisc + PT 25 m walk time (sec) 20 22.4 15.30 ‐3.10 (I) ‐16.7% (I)
    C: PT   20 18.6 14.60    
Kalay 1997 1‐4 wk E: Orthovisc + PT Flexion (degrees) 20 126.00 130.00 2.70 (I) 2.1% (I)
    C: PT   20 128.50 129.80    
Kalay 1997 5‐13 wk E: Orthovisc + PT Activity pain (0‐100 mm VAS) 20 46.8 6.10 ‐16.2 (I) ‐43.7% (I)
    C: PT   20 37.1 12.60    
Kalay 1997 5‐13 wk E: Orthovisc + PT Spontaneous pain (0‐100 mm VAS) 20 26.1 1.70 ‐8.1 (I) ‐16.3% (I)
    C: PT   20 22.1 5.80    
Kalay 1997 5‐13 wk E: Orthovisc + PT Night pain (0‐100 mm VAS) 20 24.3 1.60 ‐5.9 (I) ‐27.2% (I)
    C: PT   20 21.7 4.90    
Kalay 1997 5‐13 wk E: Orthovisc + PT 25 m walk time (sec) 20 22.4 13.30 ‐4.90 (I) ‐26.3% (I)
    C: PT   20 18.6 14.40    
Kalay 1997 5‐13 wk E: Orthovisc + PT Flexion (degrees) 20 126.00 130.00 2.70 (I) 2.1% (I)
    C: PT   20 128.50 129.80    
Karatay 2004 1‐4 wk E: Orthovisc WOMAC pain (0‐20 Likert) 20 11.2 6.4 ‐0.8 (I) ‐7.4% (I)
    C: Hylan G‐F 20   20 10.8 6.2    
Karatay 2004 1‐4 wk E: Orthovisc WOMAC function (0‐68 Likert) 20 35.0 7.4 ‐3.2 (I) ‐10.0% (I)
    C: Hylan G‐F 20   20 31.9 7.5    
Karatay 2004 1‐4 wk E: Orthovisc WOMAC stiffness (0‐8 Likert) 20 3.8 1.8 ‐0.2 (I) ‐5.6% (I)
    C: Hylan G‐F 20   20 3.6 1.8    
Karatay 2004 1‐4 wk E: Orthovisc SF intercellular adhesion molecule‐1 (ICAM‐1) 20 19.2 11.1 ‐0.3 (I) ‐1.7% (I)
    C: Hylan G‐F 20   20 17.8 10.0    
Karatay 2004 1‐4 wk E: Orthovisc SF vascular cell adhesion molecule‐1 (VCAM) 20 40.5 14.2 1.3 (W) 3.4% (W)
    C: Hylan G‐F 20   20 37.8 10.2